Here is a formal academic-style abstract:

Title: Updates in Systemic Therapy for Metastatic Breast Cancer: Insights from the 2023 NCCN Guidelines
Abstract: This study reviews the updated NCCN Guidelines for stage IV breast cancer, emphasizing the integration of tumor biology and clinical factors in informing systemic therapy decisions. The 2023 guidelines reflect emerging evidence and evolving treatment paradigms, providing clinicians with evidence-based recommendations to optimize patient outcomes in metastatic breast cancer. Key updates and their implications for clinical practice are discussed.